About this page
Insider trades reported on SEC Form 4: when the people who run a company buy or sell its shares with their own money.
How to read it
- Form 4
- The form a company insider (officer, director or owner of more than 10%) must file with the SEC within two business days of buying or selling the company's shares.
- Buy (P) and Sell (S)
- Open-market purchases and sales. Gifts, option exercises and automatic tax withholding are left out because they say little about what the insider thinks.
- Value
- Shares times price, as reported on the filing.
- 10b5-1
- A trade made under a plan set up in advance. Planned sales are common and usually say less than an unplanned purchase.
- Late filing
- A Form 4 filed more than two business days after the trade.
- Vs. S&P 500
- How the stock did after the trade minus how the overall market did in the same weeks.
A real example
In January 2016, when bank stocks were falling, JPMorgan Chase CEO Jamie Dimon bought 500,000 JPMorgan shares with his own money, worth about $26 million. His Form 4 made the purchase public within days, and investors read it as a strong sign of confidence.
Explain it like I'm 13
If the coach of a team bets his own allowance that his team will win, that tells you something. A Form 4 is the note a company boss must hand in whenever he buys or sells his own company's shares, so everyone can see it.
Data from public SEC filings and congressional reports. Information, not investment advice. Check every number against the filing linked on the page.
Kura Oncology, Inc. (KURA) Insider Trading
13 open-market trades reported since Aug 17, 2026: 2 purchases worth $2.35M and 11 sales worth $1.71M.
By insider
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| Mollie Leoni | Chief Medical Officer | 0 | $0 | 2 | $440K |
| Brian T. Powl | Chief Commercial Officer | 0 | $0 | 3 | $397K |
| Teresa Brophy Bair | General Counsel | 0 | $0 | 2 | $486K |
| Kathleen Ford | COO | 0 | $0 | 2 | $112K |
| Thomas James Doyle | SVP | 0 | $0 | 1 | $48K |
| Francis Burrows | Chief Scientific Officer | 0 | $0 | 1 | $225K |
| Troy Edward Wilson | CEO | 2 | $2.35M | 0 | $0 |
All trades
| Filed | Insider | Type | Value | 3 mo. after |
|---|---|---|---|---|
| Sep 29 | Mollie LeoniChief Medical Officer | ▼ SELL | $310K | |
| Sep 29 | Brian T. PowlChief Commercial Officer | ▼ SELL | $179K | |
| Sep 29 | Brian T. PowlChief Commercial Officer | ▼ SELL | $166K | |
| Sep 29 | Mollie LeoniChief Medical Officer | ▼ SELL | $131K | |
| Sep 29 | Teresa Brophy BairGeneral Counsel | ▼ SELL10b5-1 | $89K | |
| Sep 29 | Kathleen FordCOO | ▼ SELL10b5-1 | $72K | |
| Sep 29 | Thomas James DoyleSVP | ▼ SELL | $48K | |
| Sep 29 | Kathleen FordCOO | ▼ SELL10b5-1 | $39K | |
| Sep 25 | Francis BurrowsChief Scientific Officer | ▼ SELL | $225K | |
| Aug 24 | Troy Edward WilsonCEO | ▲ BUY | $1.24M | |
| Aug 24 | Brian T. PowlChief Commercial Officer | ▼ SELL10b5-1 | $52K | |
| Aug 21 | Teresa Brophy BairGeneral Counsel | ▼ SELL10b5-1 | $398K | |
| Aug 17 | Troy Edward WilsonCEO | ▲ BUY | $1.11M |